Third Rock Ventures III, L.P. 3
3 · Relay Therapeutics, Inc. · Filed Jul 15, 2020
Insider Transaction Report
Form 3
Third Rock Ventures III, L.P.
10% Owner
Holdings
Series B Convertible Preferred Stock
→ Common Stock (17,427 underlying)- (indirect: See Footnotes)
Series B Convertible Preferred Stock
→ Common Stock (17,427 underlying) Series A Convertible Preferred Stock
→ Common Stock (9,970,454 underlying)- (indirect: See Footnotes)
Series A Convertible Preferred Stock
→ Common Stock (2,793,770 underlying) - 563,234
Common Stock
Footnotes (7)
- [F1]These shares are directly held by Third Rock Ventures III, L.P. ("TRV III").
- [F2]The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of the reporting persons, except for TRV III, disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
- [F3]Each share of Series A Preferred Stock is convertible into shares of the Issuer's Common Stock on a 1-for-3.55092 basis into the number of shares of common stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock has no expiration date.
- [F4]These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV").
- [F5]The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
- [F6]Each share of Series B Preferred Stock is convertible into shares of the Issuer's Common Stock on a 1-for-3.55092 basis into the number of shares of common stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock has no expiration date.
- [F7]Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.